

LISTING OF THE CLAIMS

The following listing of the claims replaces all prior claims in the application:

1. (Currently Amended) A method for inducing T-cell tolerance or non- responsiveness of donor T-cells to desired alloantigen-bearing cells *ex vivo* comprising the following:
 - (i) providing a culture containing donor tissue containing donor T-cells;
 - (ii) producing a mixed lymphocyte reaction culture by adding to said donor T-cell culture alloantigen-bearing cells obtained from a recipient;
 - (iii) adding an anti-gp39 antibody ~~or a gp39-binding fragment thereof~~ to the resultant mixed lymphocyte reaction culture;
 - (iv) maintaining ~~these cells in~~ the mixed lymphocyte reaction culture *ex vivo* for a sufficient time to render the donor T-cells substantially tolerant or non-responsive to said alloantigen-bearing cells, and
 - (v) assaying *ex vivo* for induction of donor T-cell tolerance or non-responsiveness.
2. (Original) The method of Claim 1, wherein the tissue containing donor T-cells is donor bone marrow or peripheral blood cells.
3. (Canceled)
4. (Currently amended) The method of Claim 1, wherein the gp39 ~~antagonist~~ antibody is an anti-human gp39 monoclonal antibody.
5. (Previously Presented) The method of Claim 4, wherein said anti-gp39 antibody is a chimeric or humanized anti-human gp39 monoclonal antibody.
6. (Currently amended) The method of Claim 1, wherein the donor T-cells are cultured in step ~~iv~~ (iv) for a time ranging from about 1 to 30 days.
7. (Original) The method of Claim 6, wherein said time ranges from 5 to 15 days.

{W:\20052\1200522us1\00352240.DOC { } }

8. (Currently Amended) The method of Claim 1, wherein the alloantigen-bearing cells ~~comprise cells or tissue obtained from a potential transplant recipient that has~~ have been treated to deplete recipient T-cells.

9. (Previously Presented) The method of Claim 8, wherein recipient T-cell depletion is effected by irradiation.

10. (Currently Amended) The method of Claim 1, wherein the donor T-cells that have been determined to be tolerized by the assay of step (v) are transplanted into a recipient in need of such transplantation.


11. (Original) The method of Claim 10, wherein the recipient is in need of immune reconstitution as a result of disease or disease treatment.

12. (Canceled)

13. (Currently amended) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness comprises measuring IL-2 concentration in the cell culture medium supernatants of the donor T-cells cultured in step ~~iv~~ (iv) and of control donor T-cells, wherein detection of reduced IL-2 concentration in the supernatant of the donor T-cells cultured in step ~~iv~~ (iv), relative to ~~that of~~ the IL-2 concentration in the supernatant of the control T-cells, is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.

14. (Withdrawn) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness comprises measuring the concentration of interferon-gamma in the cell culture medium supernatants of the donor T-cells cultured in step iv and of control donor T-cells,

wherein detection of reduced interferon-gamma concentration in the supernatant of the donor T-cells cultured in step iv relative to that of the control T-cells is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.

{W:\20052\1200522us1\00352240.DOC  }

15. (Withdrawn) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness comprises assaying to detect at least one antigen selected from the group consisting of L-selectin, ICAM-1, and CD45 in the donor T-cells cultured in step iv and control donor T-cells,

wherein detection of an increased amount of L-selectin or ICAM-1, or a reduced amount of CD45 in the donor T-cells cultured in step iv relative to that in the control donor T-cells is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.